These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20129550)

  • 1. Second-generation drug-eluting stents and the continuous need for rapidly available real-world data.
    Mukherjee D; Moliterno DJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1236-9. PubMed ID: 20129550
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-eluting stents: more dollars than sense?
    Garg S; Eisenberg MJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1188-9. PubMed ID: 20129544
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Wijns W; Fajadet J; Mauri L; Edwards R; Cowper PA; Kong DF; Anstrom KJ
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1178-87. PubMed ID: 20129543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting stents: safe but not sufficient.
    Vogel RA
    JACC Cardiovasc Interv; 2009 Jun; 2(6):513-4. PubMed ID: 19539254
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Eisenstein EL; Leon MB; Kandzari DE; Mauri L; Edwards R; Kong DF; Cowper PA; Anstrom KJ;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1199-207. PubMed ID: 20129546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravascular ultrasound optimization of drug-eluting stents: still not enough data.
    Leesar MA
    Catheter Cardiovasc Interv; 2010 Mar; 75(4):584-5. PubMed ID: 20333656
    [No Abstract]   [Full Text] [Related]  

  • 7. Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007.
    Daemen J; Simoons ML; Wijns W; Bagust A; Bos G; Bowen JM; Braunwald E; Camenzind E; Chevaliers B; DiMario C; Fajadeto J; Gitt A; Guagliumi G; Hillege HL; James S; Jüni P; Kastrati A; Kloth S; Kristensen SD; Krucoff M; Legrand V; Pfisterer M; Rothman M; Serruys PW; Silber S; Steg PG; Tariah I; Wallentin L; Windecker SW; Aimonetti A; Allocco D; Berenger M; Boam A; Calle JP; Campo G; Carlier S; de Schepper J; Di Bisceglie G; Dobbels H; Farb A; Ghislain JC; Hellbardt S; ten Hoedt R; Isaia C; de Jong P; Lekehal M; LeNarz L; Mhullain FN; Nagai H; Patteet A; Paunovic D; Potgieter A; Purdy I; Raveau-Landon C; Ternstrom S; Van Wuytswinkel J; Waliszewski M;
    EuroIntervention; 2009 Jan; 4(4):427-36. PubMed ID: 19284063
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term outcomes after coronary bare-metal-stent and drug-eluting-stent implantations: a 'real-world' comparison among patients with diabetes with diffuse small vessel coronary artery disease.
    Koh AS; Chia S; Choi LM; Sim LL; Chua TS; Koh TH; Tan JW
    Coron Artery Dis; 2011 Mar; 22(1):96-9. PubMed ID: 21164343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of the Endeavor stent in de novo native coronary artery lesions updated with contemporary data.
    Remak E; Manson S; Hutton J; Brasseur P; Olivier E; Gershlick A
    EuroIntervention; 2010 Feb; 5(7):826-32. PubMed ID: 20142198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug-eluting stents for ST-segment elevation myocardial infarction: treatment of choice or is discretion the better part of valor?
    Rihal CS
    JACC Cardiovasc Interv; 2008 Jun; 1(3):233-5. PubMed ID: 19463305
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparing cost aspects of coronary artery bypass graft surgery with coronary artery stenting.
    Birim Ö; Bogers AJ; Kappetein AP
    J Cardiovasc Surg (Torino); 2012 Oct; 53(5):641-50. PubMed ID: 22252542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetes and drug-eluting stents: what you get and what you don't.
    Marso SP
    JACC Cardiovasc Interv; 2008 Apr; 1(2):148-9. PubMed ID: 19463292
    [No Abstract]   [Full Text] [Related]  

  • 13. It's not the dye, but the "die" in dialysis: which coronary revascularization strategy really is best?
    Butman SM
    Catheter Cardiovasc Interv; 2010 Dec; 76(7):949-50. PubMed ID: 21108371
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry.
    Tamburino C; Barbagallo R; Capodanno D; di Matteo S; Colombo GL; Recchia M; Ciriminna S;
    J Cardiovasc Med (Hagerstown); 2009 Apr; 10(4):322-9. PubMed ID: 19430343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
    Rodriguez AE; Rodriguez-Granillo AM; Antoniucci D; Mieres J; Fernandez-Pereira C; Rodriguez-Granillo GA; Santaera O; Rubilar B; Palacios IF; Serruys PW;
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):385-94. PubMed ID: 22109997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DES editorial. Is there a survival benefit?
    Thomas DM
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):644-5. PubMed ID: 18360857
    [No Abstract]   [Full Text] [Related]  

  • 18. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting.
    Chacko R; Mulhearn M; Novack V; Novack L; Mauri L; Cohen SA; Moses J; Leon MB; Cutlip DE
    JACC Cardiovasc Interv; 2009 Jun; 2(6):498-503. PubMed ID: 19539252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Each generation improves on the last (in cardiology): Bayesian thinking, the randomized clinical trial, and directed evolution.
    Morrison DA
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1018-9. PubMed ID: 21598353
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.